[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"virologic-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:virologic-failure":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100467975","a-randomized-clinical-trial-to-evaluate-solutions-for-the-management-of-virologic-failure-on-tld-in-sub-saharan-africa-100467975",false,"NCT05373758","A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa","A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure for Individuals on Tenofovir, Lamivudine, and Dolutegravir (TLD) in Sub-Saharan Africa","RESOLVE","Inclusion Criteria:\n\n* Age 15 years and above\n* Enrolled in HIV care at one of the study clinics\n* History of two HIV-1 RNA viral load measurements \\>1,000 copies\u002FmL while on TLD\n* On TLD for at least 12 months\n* Lives within 100 kilometers of study clinic\n\n  * Pregnant women are eligible for enrollment.\n\nExclusion Criteria:\n\n* Plans to transfer out of the clinic within the next 48 weeks\n* Plans to move out of the study catchment area within the next 48 weeks\n* As determined by chart review, we will exclude those with known virologic failure on protease inhibitors or exposure to integrase strand transfer inhibitors other than dolutegravir.","ALL","15 Years",{"count":20,"type":21},648,"ESTIMATED","INTERVENTIONAL",[24],"NA","The RESOLVE trial is an open, parallel arm, randomized clinical trial which aims to determine the optimal strategy for management of virologic failure on antiretroviral therapy (ART) with tenofovir, lamivudine, and dolutegravir (TLD) in sub-Saharan Africa. The primary outcome of interest will be viral suppression to \\\u003C50 copies\u002FmL at 48 weeks using the FDA snapshot definition. The study will be conducted in Uganda and South Africa.",[27,28,29],"HIV Infections","AIDS","Virologic Failure",[31,32,33,34],"ART","Medication Adherence","Drug resistance","Dolutegravir","RECRUITING","2026-03-17",{"date":38,"type":39},"2026-03-19","ACTUAL",{"date":41,"type":39},"2024-02-07",{"date":43,"type":21},"2027-06-30",{"name":45,"class":46},"Massachusetts General Hospital","OTHER",3]